Emergent BioSolutions sells RSDL decontamination kit to SERB for $75M

Emergent BioSolutions Inc.

Cash purchase price of $75M at closing; additional $5M milestone payment for component sourcing.
Sale includes Hattiesburg, MS manufacturing facility, IP, inventory, and marketing authorizations; employees to join SERB.
Emergent's Winnipeg facility will manufacture bulk lotion for SERB under long-term supply agreement.
SERB assumes existing RSDL supply contract with U.S. Department of Defense.
Net proceeds expected to reduce debt by >$150M, targeting elimination of Junior Capital Raise requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.